Karyopharm Therapeutics Inc.
NASDAQ:KPTI · NASDAQ Global Select
+$0.50 today
Vol 0.32M · Avg 0.86M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
66.9%
avg 22.5%
ROIC
-236.6%
avg -86.8%
ROA
-180.8%
avg -67.6%
Analysis
ROE is currently the strongest return metric at 66.9% versus its period average of 22.5%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Reshma Rangwala | Executive Vice President, Chief Medical Officer & Head of Research | $1.82M | — | 48 | $56,829.00 | 0.25% |
Sharon Shacham | Co-Founder & Chairman of Scientific Advisory Board | $1.40M | — | 56 | $90,000.00 | 0.40% |
Richard A. Paulson | President, Chief Executive Officer & Director | $1.24M | — | 59 | $269,747.00 | 1.19% |
Stuart Poulton | Executive Vice President & Chief Development Officer | $971,551.00 | — | 53 | $94,821.00 | 0.42% |
Lori A. Macomber | Executive Vice President, Chief Financial Officer & Treasurer | $712,680.00 | — | 55 | $269,747.00 | 1.19% |
Michael J. Mano | Executive VP, Chief Legal Officer & Secretary | $625,075.00 | — | 49 | $15,508.00 | 0.07% |
Amama Sadiq | Senior Vice President of Global Medical & Scientific Affairs | — | — | — | — | — |
Brendan Twohig Strong | Senior Vice President of Investor Relations | — | — | — | — | — |
Brian Austad | Senior Vice President of Pharmaceutical Sciences | — | — | — | — | — |
James Accumanno | Chief Compliance Officer | — | — | — | — | — |
Kristin Abate | Vice President, Chief Accounting Officer & Assistant Treasurer | — | — | — | $23,801.00 | 0.11% |
Lisa DiPaolo | Executive Vice President & Chief Human Resource Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
26
$363,842.67
Net Sentiment
$363,842.67
Net selling
Most Active
Abate Kristin
7 transactions
1–10 of 26
Analysis
Insiders reported 0 buys worth $0.00 and 26 sells worth $363,842.67 over the last 12 months. That adds up to net selling of $363,842.67. Abate Kristin was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -26.7% | +68.2% (15yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at -26.7% over three years. Forward estimates point to Revenue at +68.2% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
X4 Pharmaceuticals, Inc.
NASDAQ:XFOR
$377.28M
Mersana Therapeutics, Inc.
MRSN
$145.36M
Telomir Pharmaceuticals, Inc. Common Stock
TELO
$43.32M
FibroGen, Inc.
FGEN
$36.69M
INmune Bio, Inc.
INMB
$32.97M
Aligos Therapeutics, Inc.
ALGS
$32.67M
Barinthus Biotherapeutics plc
BRNS
$27.41M
Senti Biosciences, Inc.
SNTI
$25.24M
Medicus Pharma Ltd. Common Stock
MDCX
$7.44M
CEL-SCI Corporation
CVM
$7.42M
Who manages KPTI?
Karyopharm Therapeutics Inc. (KPTI) lists 12 active executives. The top listed executive is Amama Sadiq, Senior Vice President of Global Medical & Scientific Affairs.
Are KPTI insiders buying or selling?
Recent insider activity shows net buying of $79,308.15.
Explore More
Continue the stock analysis
Jump to another research area for this company.